Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F23%3A00079637" target="_blank" >RIV/00159816:_____/23:00079637 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/23:00130973 RIV/61989592:15110/23:73620559

Result on the web

<a href="https://www.mdpi.com/2079-6382/12/3/437" target="_blank" >https://www.mdpi.com/2079-6382/12/3/437</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/antibiotics12030437" target="_blank" >10.3390/antibiotics12030437</a>

Result language

angličtina

Original language name

Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review

Original language description

The emerging resistance of Gram-negative bacteria is a growing problem worldwide. Together with the financial cost, limited efficacy, and local unavailability of newer antibiotics or their combinations, it has led to the reintroduction of colistin as a therapeutic alternative. Despite its protracted development and availability on the market, there is now a complex maze of questions surrounding colistin with a more or less straightforward relationship to its safety and efficacy. This review aims to offer a way to navigate this maze. We focus on summarizing the available literature regarding the use of colistin in critically ill patients, particularly on stability, pharmacokinetics, methods for determining plasma concentrations, and therapeutic drug monitoring benefits and limitations. Based on these data, we then highlight the main gaps in the available information and help define directions for future research on this drug. The first gap is the lack of data on the stability of intravenous and nebulization solutions at clinically relevant concentrations and under external conditions corresponding to clinical practice. Furthermore, pharmacokinetic-pharmacodynamic parameters should be validated using standardized dosing, including a loading dose. Based on the pharmacokinetic data obtained, a population model for critically ill patients should be developed. Finally, the interference of colistin with extracorporeal methods should be quantified.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30303 - Infectious Diseases

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Antibiotics-Basel

ISSN

2079-6382

e-ISSN

2079-6382

Volume of the periodical

12

Issue of the periodical within the volume

3

Country of publishing house

CH - SWITZERLAND

Number of pages

17

Pages from-to

—

UT code for WoS article

000983473900001

EID of the result in the Scopus database

—